Shire Plc delivered a 7% increase in product sales to $3.5 billion in the third quarter, which was heavily weighted by revenue from its haematology and immunology franchises, acquired following the company’s takeover of Baxalta Inc in 2016. ---Subscribe to MedNous to access this article--- Company News
